Ipca Laboratories Limited (IPCALAB) Earnings Call Transcript
February 16, 2026
Earnings Call Speaker Segments
Good day, everyone, and welcome to the Ipca Laboratories earnings conference call. Please remain on the line. The call is going to start in just a moment. Good day, ladies and gentlemen, and welcome to the Ipca Laboratories earnings conference call for Q3 FY, hosted by DAM Capital. As a reminder, everyone dialed in will be in listen-only mode, and following the conclusion of the presentation, there will be a chance for you to pose questions. If you require any help during this call, please alert an operator by pressing star followed by zero on your touchtone phone. Kindly be aware that this conference is being recorded. I'll now turn the conference over to Mr. Nitin Agarwal of DAM Capital. Thank you, and the floor is yours.
Thanks. Hello and good afternoon, everybody, and a very warm welcome to the Ipca Labs Q3 FY26 post-earnings call, hosted by DAM Capital Advisors Limited. Joining us today representing Ipca Labs management, we have Mr. A.K. Jain, our Managing Director, and Mr. Harish Kamath, Corporate Counsel and Company Secretary. I'll hand the call over to Mr. Jain for the opening comments, and after that we'll open the floor for questions. Please go ahead, sir.
Good afternoon, and thank you, Nitin and DAM Capital, for arranging this call. The earnings call today, along with the discussions and responses provided, might contain forward-looking statements that reflect our present business expectations, and these need to be considered alongside the risks that the pharmaceutical business encounters. Our actual future financial performance could end up differing from what is projected and perceived. You are free to apply your own judgment regarding the information shared during this call. For Q3 FY26, our domestic business has posted growth of roughly 12% for the quarter. As of mid-December 2026, our ranking stayed at 16th, according to IQVIA. We have outplaced the IPM in both the chronic and acute segments. At the overall level, IPM grew by approximately 8.9%, while IPCA grew by approximately 10.6%. In the acute segment, IPM growth came in at approximately 6.9%, and our growth was approximately 8.4%. In the chronic segment, IPM growth stood at approximately 12%, and we grew this business by approximately 15%, per IQVIA. Ipca's market share for the quarter remained at approximately 2.08% as of mid-December 2025. Our export formulation business delivered growth of approximately 17% in Q3, and across the nine months period, export formulations achieved growth of approximately 6%, moving from INR 1,395 crore to approximately INR 1,477 crore.
During the quarter, the API business stayed flat at roughly INR 317 crore. Across the nine months of this financial year, that segment has expanded by approximately 14%, reaching about INR 1,051 crore, up from INR 924 crore. Our Q3 consolidated business posted growth of roughly 6.5%, coming in at around INR 2,245 crore, from INR 2,393 crore. Over the nine months of the current financial year, the consolidated business grew by about 8.44%, to INR 7,258 crore from INR 6,993 crore. Standalone EBITDA margin for the quarter improved to 26.09%, versus roughly 24.25% in Q3 FY26, an overall gain of about 1.81%. Consolidated EBITDA margin for Q3 FY26 stands at approximately 22.15%. That compares with 19.87% in Q3 25, an improvement of roughly 2.28%. For the first nine months of this financial year, EBITDA margins are around 20.79%, compared with 19.18% in the first nine months of last financial year, an improvement of almost about 1.61%. Now that I've laid out the broad numbers, I'd ask participants to begin asking questions.
Thanks so much. At this point we'll open things up for questions. To ask one, just hit star and one on your touchtone phone. Should you want out of the queue, press star and two. We ask that participants use their handsets when posing a question. Ladies and gentlemen, we'll pause briefly while the queue fills up. Our first question comes from Anchal Zaran at Lotus Wealth. Please go ahead.
Regarding Unichem, sir, our COGS currently sits at 45%, and if we assume that holds steady over the coming quarters — say the company is targeting 18%-20% EBITDA margins within roughly 18 to 24 months — then with operating leverage plus some additional cost reductions, could you lay out a roadmap on that?
Regarding Unichem’s business in the last and current financial years, some issues arose since they lost certain US businesses while gaining others. So on the whole, Unichem’s business—I think the basic business, what they were doing aside from the Ipca portfolio—grew only about 2% in the current financial year. And the business that was lost is mainly high-volume business, where the plants were also recovering a good amount of overhead. So that loss of business has had a small impact on Unichem’s overall margins, and their EBITDA margins this quarter are almost around, close to around 8% in the current financial year. Their European business is now improving, and more and more filings are also taking place, so going forward we hope to do better there. And as far as the US business is concerned, their overall business growth is good because of, let’s say, the portfolio they have received from Ipca. So overall, I think in the first nine months of the current year, the US business has grown by around, almost around 15%, 15%. And for the quarter, the US business has grown by around 17%. Yeah.
Regarding EBITDA improvement, could you give us some kind of roadmap on that? Are there any plans in place for it—for boosting the EBITDA margin?
Better EBITDA margins are going to come from, let's say, capacity being utilized more fully, a stronger U.S. business — which we hope to achieve in time to come — and also from the improvement in the business that is currently happening in Europe. Yeah.
Understood, sir. And as for the proceeds the company holds, which come to roughly INR 275 crore—
Which one was that from?
Could you give us some detail on that land sale? Do you have any plans for it?
Their cash flow, let's say, took a hit as well, since they had to pay a European Union fine tied to past patent appeal matters, some issues there. So roughly INR 181 crore has gone toward that. As things stand, their cash flow is healthy right now. They're holding just over INR 250 crore in the bank. At present, there are barely any expansion plans apart from the one solar project, which is underway to use more green energy, and that will involve a capital outlay of roughly INR 50 crore. So beyond that, they don't have any major capital expenditure plan of any kind. Yeah.
Alright, thank you, sir.
Thanks. Our next question comes from Surya Narayan Patra at PhillipCapital. You have the floor.
Yeah, thanks for giving me the chance, sir. Sir, my first question concerns the growth in promotional brands that we've observed. I think it's been quite a strong gain after a number of quarters, which is what we're seeing. Is there anything that can be credited for that growth, or is it partly driven by the depreciation of the rupee?
West Africa, I believe, performed quite well this quarter, and on the whole, for the full year, that region — which is more a French-speaking African market and so on — has seen growth of roughly 41% across the first nine months, while in Q3 it grew by approximately 69%. So that's one part of the business. Latin America is up 20%, the Middle East and Africa by about 27%. East Asia stands at nearly 36%. The CIS business was broadly flat during the quarter. So overall, business growth is solid. Across the first nine months, it has risen by roughly 14%, but for the entire year, we don't anticipate business growth holding even at 14%. It will likely come in around 11% or so for the first 9 months of the current year.
Alright. So, regarding the domestic formulation business, we've been growing faster than the industry, and in terms of growth we've ranked among the top five or top 10 players. But it does appear that, based on Pharmarack, our growth would also have moderated somewhat. Looking forward, if we consider GLP as a key growth driver for the industry overall, we aren't present in the first wave of GLP commercialization. So with that in mind, is it likely that we would underperform our larger peers when it comes to growth in the domestic market?
And so we're also pursuing in-licensing, so yes, we, we, we can come with the GLP. It's not that we won't manufacture in-house, but yes, we're looking for those kinds of opportunities. And overall, let's say for us, this growth is going to stay better because the trend, whatever we're seeing, that is better. Let's say our pain segment, which is over 50% now, is continuously driving the business. In this quarter also, pain has grown by around 13%. Our cardiovascular business — because last year, at the beginning of the current year, we did the reorganization. So for the first few months, that growth was a little lower because of restructuring. Now, that business has also started delivering good growth, and I think for the current quarter, the cardiovascular domestic business has grown by around 16%, the anti-diabetes business has grown by 14%. So overall, that business is also good. In spite of anti-malaria declining by almost around 21% in this quarter, other businesses did really very well, like the CNS business has grown by around 19%, the Derma business has grown by around 22%, Urology has grown by around 17%, and other businesses, small, small businesses, which have also grown by 13%.
All in all, I'd say things are going well, and we anticipate that we'll keep outperforming the market. Yes.
So, on gross margin, sir, we saw a fairly meaningful positive surprise this quarter. Was there any factor specific to the quarter, or is it the rupee depreciation, or is it product mix? What would have driven this, and how sustainable do you think this gross margin is as we go ahead?
So overall, gross margin depends on how much the top line grows. When domestic sales rise, when the branded business expands — and there we enjoy healthy margins — and even in the generic businesses, margins are quite strong, and growth there was strong as well. The institutional business did decline this quarter, but our other businesses expanded nicely, and margins in those are very good. So on a standalone basis, taking it all together, the ratio of material cost to sales has fallen to roughly 24%. Material prices are broadly steady, drifting slightly upward, though not by much. It's entirely the shift in product mix and the faster growth of higher-margin businesses during this quarter that also produced a better margin. Looking at the first nine months of the current year as well, we have improved by nearly around — I'm speaking of standalone here,
Yes.
By roughly 336 basis points, moving from 28.73% material cost in last year's first nine months. The material cost ratio sits at about 25.37%. So that's an improvement of nearly 3.36 percentage points. And in this quarter, the gain is slightly larger — around 3.64%. But on the whole, I think for the full year it will stay at maybe 3.3% or 3.4%, that kind of overall improvement in the material cost to sales ratio, standalone for Ipca. Yeah.
All right, just one final point from me, sir. Looking forward, when it comes to where we're concentrating, what would the main areas be — whether that's integrated manufacturing, getting the most out of the US, the Unichem integration, or building capabilities around biosimilars, injectables, and hormones? So what would you say are a couple of the key focus areas that ought to drive growth over, say, the next two years?
These all represent our priority areas, since you have different teams, and each one has its own priority. Then, domestic, let's say, stays a priority area as well.
Mm-hmm.
The branded side is a focus area as well, and so are your generic businesses, since separate teams handle those operations and they are. Our total filings are also accumulating across each of these markets. R&D output has grown at this point, so that too will have a—in the future that will likewise carry a stronger effect on the generics business overall, and ROW filings are climbing as well. We expect to perform well across every one of these businesses in the period ahead.
Alright, yeah.
On the biosimilar side, we currently have 5 candidates, and for 2 products we've already begun the technology transfer process; we hope manufacturing will kick off soon.
Is that even aimed at advanced markets, sir?
That's going to cover every market worldwide. I believe we've already gotten feedback on our regulatory framework from the UK's MHRA, from the European authorities, and from the US FDA as well. So we've received that input on protocols and everything from all three agencies. So things are proceeding along those lines. Yeah.
Sure. Yeah. Thanks, sir. Best of luck to you.
Thanks.
Thanks. If you'd like to pose a question, you can press star and one. Our next question comes from Shashank Krishna Kumar at Emkay Global. Go ahead, please.
Hi, thanks for taking my question. My first one concerns the domestic API business. I think that in our export API, broadly speaking, realizations have begun to stabilize. But where the domestic API is concerned, I just wanted to get some sense of whether the YoY decline is still largely a function of realizations staying under pressure, or whether volumes have also sort of come down. Just wanted to get some sense around that.
On the domestic side, I'd say we also have a sizable anti-malarial business. That segment has softened a bit, and the impact shows. On top of that, some tirzepatide business that used to be manufactured at Krebs' facility has now declined. Beyond those items, there isn't any meaningful difference overall.
Understood. So second, regarding the margin expansion we saw this quarter on a YOY basis: I think consolidated margin expansion is somewhat higher compared with what we've seen on a standalone basis. Though Unichem margins, I think, have declined. So I wanted some color on what's driving that, and is it also sort of tied to the fact that, excluding Unichem revenues, if I look at it for the other sub, that is a bit lower this quarter — so is that connected to that? I wanted some color around that.
Essentially, the Ipca standalone operation is the main driver, and the nutraceutical segment we have within Tropic Wellness is performing very strongly as well. So yes, both of those operations have performed well, and that's what's powering the business and their margins, yeah.
Understood, sir. Thanks very much, and best wishes to you.
Thank you. Anyone who would like to pose a question can press star and one now. Our following question comes from Dharmil Shah at DAM Capital. The line is yours.
Hi, thanks for taking my questions. I'd like to focus specifically on Unichem. During the quarter, our revenues fell 2%, and you've already noted that this is partly due to losing market share in the key products. But that was already reflected in H1 revenues. So has there been any additional market share loss in Q3 that we've seen?
No, actually, that drop began in Q2. It may keep going for another 1 or 2 quarters.
All right, I understand. What's your plan for winning back that market share? Is it something that happens annually, where you see the business share loss in the market?
We're planning to bring 4 to 5 additional molecules into the U.S. market. And in situations where we've lost market share on 2 to 3 major molecules, we're taking the steps needed to win that share back.
Alright.
All at once, with competition picking up and prices coming down, they lost a portion of their business. We're going to win that business back. That could take an additional one or two quarters.
Typically, these agreements run for 12 months, or — I mean, what's the usual frequency there—
Not necessarily, not necessarily. Three months, six months. There's no hard and fast rule here—everything applies to a single, one, twelve-month contract only.
Got it. So what's driving that confidence? Is it that you're picking up share within the same molecules, or are you counting on the new product launches?
No, with that same molecule we’ll also win back whatever market share we’ve lost, though at a lower price. And on top of that, new products are continuing to be launched in the marketplace.
Got it. So should we take it that gross margins — and really, EBITDA margins overall — are going to be under pressure, even though we might get—
It might be one or two more quarters where it’s definitely under pressure. After that, it should get better.
Got it. And once that's posted too — I mean, if we're bidding at prices that are lower, then gross margin ought to come under pressure, correct?
No, but they'll be handling some Ipca business as well, and that side is developing nicely and expanding. So Unichem serves as our marketing partner in the U.S., and we've launched five molecules already. Over a span of, let's say, 1, 1 and a half year, we've now captured a substantial amount of market share. And another 4 to 5 more Ipca molecules are also getting launched in the U.S. market. So Unichem U.S. will reap that benefit going forward too.
Got it. With these Ipca molecules, how large might the business become over the next 1 or 2 years? I'm just trying to get a rough sense of it.
Back when we had roughly 10 molecules in our U.S. business, about 7 to 8 years ago, we were at around INR 300 crore.
Alright.
So from that, we've launched about 5 molecules so far, and every one of them is backward integrated. We'll be launching another 4 to 5 molecules over the coming 6- to 12-month period.
Got it, understood. Just at a high level, how do you view Unichem's growth over the coming two years — FY25 and FY28? And with FY26 nearly finished now, right.
Once the filings Unichem is currently handling in Europe and elsewhere are registered and those products reach the market, its growth and margin will improve. It is also pursuing numerous registrations in the ROW branded space. Cumulatively, all of this will help the company grow its business and margin across the next 2 to 3 years.
Sure — if you were the one providing the guidance, I mean, what sort of growth would you anticipate on the top line from Unichem's business, or... and what about profit?
Look, once they recover whatever market loss they’ve got in the U.S., then over time their top line should grow somewhere in the 8%-10% range. Our goal is to get EBITDA margin initially to about 15%, perhaps within 2 to 3 years.
Alright.
We’ll ramp that up gradually to roughly 20% once all their filings and registrations come through in the European market, and that business is going to grow.
Got it, though when it comes to the Europe business—
Their manufacturing plants have plenty of capacity. Once that capacity begins to be used, their margins are going to improve on their own.
Got it. But the Europe business is going to take some time, right? Since you've only just filed the application, yeah.
Somewhere in the 1-to-2-year range. So filings are taking place — a few have already been submitted, and a few more are in the process of being filed. So it's going to take a while.
Got it, understood. On that 8%-10%, are you referring to the U.S. business, or to revenue growth overall?
No, no — overall, I’m the one speaking.
Got it. Yes, thanks a lot. That's genuinely useful, yes.
Yeah, thanks a lot.
Thanks. We’ll take the next question from Nikhil Mathur at HDFC Mutual Fund. Please go ahead.
Hello there, and thanks, sir, for the chance to speak. I have two or three questions. First, I'd like to ask about branded formulations in exports — specifically Ipca ex Unichem. You've provided guidance of roughly 11% growth for this year. Would you be willing to share an outlook for FY 2027 and 2028 too? And from a 3-year to 5-year perspective, how do we see that business taking shape?
Our promotional branded business is quite steady, except when currencies get chaotic in the market — that is the only period this business takes a hit. So overall, I think this promotional branded market should keep growing at roughly 10%-12% over a longer stretch. As for generics, I think we are... growth will now be quicker in Europe, and in the U.S. too it will be quicker. So overall, for generic businesses we expect a similar rate, roughly 10%-12% growth. The API business will see somewhat low, a bit lower growth, and the domestic business is also at roughly 10%-12% growth. So overall, for the company, growth comes in at around 10%-11%. That is broadly the overall picture. And detailed guidelines on the overall business and margins we will provide once our budget exercise for the current year is done by March, and after that we will give you the detailed guidance.
Okay, so on the promotional branded side, I get it. Sorry—on the generic side, I didn't follow. What you're saying is that even with the U.S. coming back from Ipca's standpoint, growth is only 10%-12%, correct? That's out of the INR 300 crore business that was discontinued 6 years-7 years ago. Is there any specific reason for the softness on the generic formulation side, even though the U.S. is coming back?
The main issue there is really the uncertainty around the institutional business. That's the thing we're keeping in mind.
All right. If I set the tender business aside and leave out institutional, what would the outlook be?
Possibly another 1% or 2%, yes, in terms of growth.
All right, understood. All right then. So looking at how the EBITDA margin has been moving, I'd say this year's EBITDA margin — again, leaving Unichem out — is trending somewhat stronger than the guidance we gave over the past couple of quarters. So are there specific reasons the margins are turning out better, particularly where growth is concerned? And with that, given there's been a substantial gain over the last 2 years on the EBITDA margin front, does room still exist for further margin gains in FY 27 and FY 28? I'm referring to ex Unichem.
The margin really depends on how much the top line grows. When top line growth lands at roughly 10%-12%, you'll certainly see margin expansion of 1.5% or more.
Is that 1.5% per year, or across a two-year span?
Each and every year.
Each and every year. All right.
Yeah.
So that means there's a potential for 300 points — 300 basis points of margin improvement over the next 2 years, assuming growth stays at 10%-11%?
Yeah.
Understood. Thanks, sir. That’s useful.
Thanks. Just a quick reminder for everyone on the line — if you'd like to pose a question, you can hit star and one at this point. To submit a question, go ahead and press star and one now. Anyone who wants to ask something, feel free to press star and one. Our next question comes from Chirag with DSP Investment Managers. The line is yours.
Yeah, so thanks for giving me the chance. Sir, what's the situation with our U.S. business? Could you speak to the third quarter run rate? I realize that's included within Unichem revenue, but you don't provide the regional breakdown for Unichem. So for our Ipca U.S. business, what is that figure, and where does it stand? And if you could address the nine-month and the three-month numbers, and what the outlook is there over the next couple of years?
During Q3 of the last quarter, the US business stood at close to INR 395 crore on a consolidated basis — I'm referring to Ipca and Unichem combined. In Q3 2025, that same business came in at roughly INR 339 crore. So a growth rate of about 17% is there. This entire expansion in the US business stems largely from the Ipca portfolio. The Ipca portfolio consists of its own product plus the Ipca portfolio that was Bayshore's at the time, for which third-party products were being traded around that period. Taken together, that business has grown roughly 17%. If you look at the overall first nine months of the current year, that business is nearly around INR 1,140 crore. And in the prior year, that business was approximately INR 990 crore. There is growth of almost 15% in the US business. Most of this business growth is by and large attributable to either the Ipca portfolio and the portfolio that is Bayshore's portfolio, which has moved to Unichem. Yeah.
Sir, could you speak to the Ipca manufactured product portfolio, please?
Um, that, uh—
The figures look quite alike.
My sense is that they've already completed somewhere in the neighborhood of INR 10 million to INR 11 million in business overall. Yeah.
In 9 months?
Yeah, in 9 months.
Right. Sir, what was the exit run rate for the third quarter?
Things are going to improve on the business side.
Got it. So how are we looking at this business over the next 2 years, sir?
This topic was already addressed by Mr. Kamath. Yeah.
Chirag, we’ve got roughly 35 registrations, and 5 of those have been commercialized. Another 5 to 7 molecules should be commercialized over the next 12 months to 15 months. Gradually, each year we’ll be adding 5 or 6 new products in the U.S. market from the Ipca portfolio.
So you're not going to share a revenue figure with us?
Look, the reality is that gaining market share once a product has launched takes a very long time. Take the five products I'm marketing today — it's been nearly 2 years now, and we've finally gotten to a market share of 25%+ on most of the molecules. That's because every one of them is a molecule we're backward integrated on, and there's still room to push market share higher on these very molecules, the five we're marketing right now. So an opportunity exists, and we're putting in the work toward it.
Got it. One quick piece of feedback, sir, just incrementally. Sir, if you could also share the geographic mix of the top line for Unichem, that would help us assess the business better on a quarterly basis. If you're able to do that, it would be helpful, sir.
So look, nearly two-thirds of what they do comes out of the U.S. Beyond that, there's a modest ROW branded formulation operation, a bit of API business, and a generics business — mainly in the U.K. plus a country or two in Europe. That's it.
All right, thank you very much.
Thanks. Our following question comes from Kunal Randeria at Axis Capital, who is on the line. Kindly proceed.
Good afternoon, sir. Sir, the gross margins still confuse me. If you take out Unichem, they're already in the mid-seventies, and very few pharma companies, I think, report margins like that. And also, given that the API business, you know, would be facing lower gross margins. So I just want to understand — because a couple of years back, I think it would have been in the high sixties — what's driving this besides currency? And second, what's the ceiling, you know, for this number?
It's entirely a matter of product mix, nothing more. In whatever areas margins are stronger, those businesses happen to be expanding more quickly. Take the domestic business, for instance: our chronic segment is expanding more rapidly than the acute segment, where the margin is lower since most of that is anti-malaria business. The same holds true in the international ROW market as well, and in the generic business too.
No, I get the product mix. Sorry to press you on this, sir, but I mean, a margin in the mid-seventies, you know, like this — is that because of — hello?
Hi there.
Kunal, your sound is coming through all muffled.
My apologies.
Hello?
I’ll get back in line. I’ll get back into the queue.
Okay, please get back in the queue. Thanks. Our next question comes from Saion Mukherjee at Nomura. Go ahead.
Yeah, hi, sir. Good evening. I just had one question. Has Ipca begun submitting filings for the U.S. market? If you could share how many have been filed, and whether you see any opportunity there over the next 2, 3 years.
I believe we've already filed four times this current year, and on an annual basis, roughly five to six filings would likely take place each year.
And when do you expect those new filings to reach commercialization, if you have any timeline in mind?
That all hinges on how the approval timeline plays out. But let's say — we still have, I believe, more than 30 filings, and roughly 8, 10 approvals are still pending, past approvals, and after that, the new filing approval. So everything will hinge on how the filings mature and approvals begin to come through. Given that, it's hard to provide the numbers at this point, but yes, it will all depend on that.
Alright. Sir, could you share any color on the European business? As you know, there were some issues previously. How do you view growth in unbranded generics outside of the U.S.? Could you provide some color?
So, I'd say a lot of what we do is in smaller European geographies, plus Australia, New Zealand, and Canada — and that business is solid business. Our margins there are quite good and all. We do have some business in Europe and the UK. That business was fiercely competitive, and in that market pricing was practically a bloodbath. Plenty of products were being sold at losses there. But over the last month, we've begun to see prices recovering sharply once more, and those recoveries run as high as 30%-40%. So it's just that sort of thing that sometimes happens in the market when inventories get big — people simply try to unload material, short-expiry items and all that, which destroys pricing. So I think in the last financial year, most of our portfolios were dealing with that sort of issue. But at this point we're seeing a much better recovery, and we now hope to do better business there. Still, that's the lowest-margin business we have in the generic market. Broadly speaking, the business coming out of the Scandinavian countries and the other smaller European countries — we aren't currently in Germany, we aren't in France or Italy or markets of that kind, but we do have a good presence in Spain and other markets.
The overall margin profile is much stronger.
All right, so I’ll squeeze in one final question if that’s okay. You’ve discussed how your margins have gotten better, and we’ve noticed that improvement as well—you also said, for instance, that EBITDA margin should expand by 150 basis points. As for the steady business you have in India, I’m not sure whether you spell out the margin figure for India, but if you could share that number, that would be great. If not, then qualitatively, perhaps you could describe how the margin in the domestic business has been trending. Has it improved a lot, or has it held steady? Or if you could offer some color on how the margin in the domestic business is…
When you take a broad view, the strongest EBITDA margins we have come from the promotional branded business in international markets. The next tier—
Mm.
One would be the domestic business. The second will be the generic business, which we handle beyond the UK—other than the UK.
Um.
After that, institutional comes next, then the U.K. business last, and after that, the API business. So in terms of margin—
Alright.
When you consider the domestic business, the branded business would rank second for us, yeah.
What's the trend looking like, sir? If you could share some detail on that, and what should we expect? This is a fairly steady business, isn't it? You'd keep growing at 10%-12%, as you said.
Look, with the promotional branded business, the cost of our materials is extremely low. It's roughly 10 to 12% in terms of material cost. So any gain in that business, in the same way, at the... Because our domestic business is now also anti-malarias and all of these antibacterials-
Mm.
That's a very small piece of it, and we're shifting more toward CNS, urology, and cardiology. Those are the kinds of businesses growing at a faster clip. So the margin profile there is rising too, improving considerably. So overall, with 10%-12% growth, it's quite easy to lift the total margin—EBITDA margin—by roughly 1.5%. That's just the nature of the business quality.
Mm-hmm. Alright, sir. Thanks, sir.
Thanks. We’ll take the next question from Harsh Bhatia at Bandhan Mutual Fund. Your line is open—please go ahead.
Yep. So thanks for that. Open Audible.
Yeah.
Turning to what was said about Europe—specifically pricing and the recovery—there may be several causes behind the bulk of the price erosion, but the largest share came from matters tied to tariffs and dumping. Or was there something that stood out as one-off in that respect? Could you lay out some of the reasons why pricing in the European market deteriorated so sharply, and is the improvement we have seen over the last one month more sustainable?
That remark was about the U.K. business alone, not the European business. The European business is very steady and there is absolutely no problem there. I was referring only to the U.K. business.
Okay, to clarify one of your comments — that relates to the U.S. business. When we guide for Unichem growth, I think 8%-10% or 9%-10% over the next 2-years-3 years, that is pure Unichem growth, correct? Are we factoring in, or are we assuming, that Ipca U.S. sales will drive U.S. growth for the Unichem business? Is that how it works, or are we simply assuming the pure Unichem U.S. division grows on its own?
As we've mentioned before, during the first nine months of this current financial year, Unichem's U.S. business has seen its own portfolio come in lower, and that's due to market share loss on 1 or 2 molecules, which they're hoping to win back, perhaps within another 2 to 3 quarters. So standing alone, once they rebuild and recover that market share they lost, their portfolio should also expand by 7%-8% annually going forward, helped by the launch of 4 to 5 new molecules over the next 2 years-3 years.
Alright, sir. Thank you.
Beyond that, any growth that occurs in the Ipca US business will also count as their growth in the US market.
Alright.
Thanks. A quick reminder for everyone on the line: if you'd like to ask something, go ahead and press star and one at this point. To pose a question, just hit star and one now. If anyone out there wants to ask a question, you can press star and one right at this moment. Ladies and gentlemen, that wraps up the final question for today. At this time I'd like to pass the conference back to management for some closing remarks.
No, madam, we can wrap up this conference call now. Every question has been answered by us. There's nothing further for us to add.
All right, thanks. That brings this conference to a close on behalf of Ipca Laboratories and DAM Capital. We appreciate your participation, and you can go ahead and disconnect your lines now.
Much appreciated.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Ipca Laboratories Limited transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Ipca Laboratories Limited earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.